Table 5.
Treatment-Related TEAEs (Safety Population)
| TEAE | Abicipar Q8 (N=123), n (%) |
|---|---|
| Any term | 21 (17.1) |
| Eye disorders | 19 (15.4) |
| Conjunctival hemorrhage | 5 (4.1) |
| Eye pain | 3 (2.4) |
| Iridocyclitis | 3 (2.4) |
| Iritis | 3 (2.4) |
| Uveitis | 3 (2.4) |
| Eye irritation | 2 (1.6) |
| Vitreous floaters | 2 (1.6) |
| Vitritis | 2 (1.6) |
| Dry eye | 1 (0.8) |
| Eye swelling | 1 (0.8) |
| Eyelids pruritus | 1 (0.8) |
| Keratic precipitates | 1 (0.8) |
| Lacrimation increased | 1 (0.8) |
| Ocular hypertension | 1 (0.8) |
| Pigment dispersion syndrome | 1 (0.8) |
| Punctate keratitis | 1 (0.8) |
| Retinal hemorrhage | 1 (0.8) |
| Vision blurred | 1 (0.8) |
| Vitreous detachment | 1 (0.8) |
| Vitreous haze | 1 (0.8) |
| Injury, poisoning and complications | 3 (2.4) |
| Corneal abrasion | 2 (1.6) |
| Foreign body in eye | 1 (0.8) |
| Investigations | 2 (1.6) |
| Intraocular pressure | 2 (1.6) |
| Vascular disorders | 1 (0.8) |
| Vein rupture | 1 (0.8) |
Notes: Treatment-related TEAEs include those that in the investigator’s opinion may have been caused by the study treatment (drug or drug administration procedure) with reasonable possibility. Ocular TEAEs include events reported in either eye (study or non-study eye). Preferred terms are sorted by descending frequency. Within each preferred term, a patient is counted at most once.
Abbreviation: TEAE, treatment-emergent adverse event.